Source BBC: Scans carried out when someone is first diagnosed with multiple sclerosis can predict their long-term prognosis, research has shown.
Early MS scans ‘can predict long-term prognosis’ Read More »
Source Kings College London: “I am a third-year psychology student at King’s College London, currently assisting a PhD student, Jowinn Chew (cc’d in this email), on her research supervised by Dr Colette Hirsch and Prof Rona Moss-Morris from the Health Psychology Department. The research is focusing on identifying the cognitive mechanisms which underpin and maintain
Research request from Kings College London Read More »
Source MS Society: Join us for an afternoon with Dr Claire Rice, Neurologist and MS Researcher in Bristol. Claire will give an overview about stem cell treatment for MS including its current role in disease management and research priorities.
Source Multiple Sclerosis News Today: A new study demonstrates that intracellular sigma peptide (ISP) can promote remyelination in a mouse model of multiple sclerosis (MS).
Independent Mouse Study Reinforces Remyelinating Potential of ISP Therapy Read More »
Source Multiple Sclerosis News Today: The National Stem Cell Foundation (NSCF) announced the start of a pioneering project to investigate the impact of microgravity on the neurodegeneration associated with primary progressive multiple sclerosis (PPMS) and Parkinson’s disease.
Source BioSpace: Multiple sclerosis (MS) is an often-disabling disease of the central nervous system caused by damage to the myelin coating around the nerves.
Source Science Daily: The research shows that projection neurons are damaged by the body’s own immune cells and that this damage could underpin the brain shrinkage and cognitive changes associated with MS. These new findings provide a platform for specific new MS therapies that target damaged brain cells to be developed.
Source Medical News Toady: A Phase 3 trial is planned to confirm the safety and efficacy of oral ibudilast (MN-166) in treating people with secondary progressive multiple sclerosis (SPMS) without relapses or those whose disease is not active, MediciNova announced.
Source Multiple Sclerosis News Today: A first group of healthy volunteers in a Phase 1 trial assessing the safety and tolerability of T20K, Cyxone‘s plant protein-derived candidate for the treatment of multiple sclerosis(MS), has been dosed in a study taking place in The Netherlands, the company announced.
One of our members thought that others would find this Inside Science broadcast on Radio 4 interesting.
Inside Science – BBC Radio 4 Read More »
